OSTX
OS Therapies IncorporatedOSTX
OSTX
About: OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The companys mission is to address the significant need for new treatments in cancers of the bone in children and young adults.
Employees: 4
0
Funds holding %
of 6,780 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
0.77% more ownership
Funds ownership: 0% [Q2] → 0.77% (+0.77%) [Q3]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$8
272%
upside
Avg. target
$17.75
726%
upside
High target
$21
877%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
Maxim Group Jason McCarthy 39% 1-year accuracy 9 / 23 met price target | 272%upside $8 | Buy Initiated | 26 Nov 2024 |
EF Hutton Jason Kolbert 30% 1-year accuracy 36 / 121 met price target | 877%upside $21 | Buy Maintained | 3 Oct 2024 |
EF Hutton Jason Kolbert 30% 1-year accuracy 36 / 121 met price target | 877%upside $21 | Buy Maintained | 16 Sept 2024 |
EF Hutton Jason Kolbert 30% 1-year accuracy 36 / 121 met price target | 877%upside $21 | Buy Initiated | 3 Sept 2024 |
Financial journalist opinion
Neutral
Business Wire
2 weeks ago
OS Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update
NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today reported financial results for the third quarter of 2024 ended September 30, 2024 and provided a business update. “The third quarter was pivotal for OS Therapies as we completed our initial public offering and finished dosing the final patient enrolled in our Phase 2b clinical trial of OST-HER2 in resected,.
Neutral
Business Wire
4 weeks ago
OS Therapies to Present at The Spartan Capital Investor Conference
NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that Paul Romness, Chief Executive Officer, and Gerald Commissiong, Chief Business Officer, will present a corporate overview at The Spartan Capital Investor Conference. The conference is being held on November 4, 2024 at the Pierre Hotel in New York. The Company's participation aligns with our commi.
Neutral
Business Wire
1 month ago
Join OS Therapies' Exclusive Live Investor Webinar and Q&A Session on October 30
NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, is pleased to invite investors to a webinar on October 30, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature OS Therapies' Chairman and CEO Paul Romness, and Chief Business Officer Gerald Commissiong. They will share insight into the Company's pipeline of novel treatments f.
Neutral
Business Wire
1 month ago
OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors
NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announced the appointments of Avril McKean Dieser, MA, JD and Olivier R. Jarry, MS, MBA as independent members of the Company's Board of Directors. Collectively, Ms. McKean Dieser and Mr. Jarry bring over 50 years of biopharmaceutical executive decision-making experience to the Company, with a specific focus in comm.
Neutral
Business Wire
1 month ago
OS Therapies to Present at the LD Micro Main Event XVII
NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announces that Paul Romness, Chief Executive Officer, and Gerald Commissiong, Chief Business Officer, will present a corporate overview at the LD Micro Main Event XVII. The conference is being held on October 28 – 30, 2024 at the Luxe Sunset Boulevard Hotel in Los Angeles. Event: LD Micro Main Event XVII .
Neutral
Business Wire
1 month ago
OS Therapies to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announces that Paul Romness, Chief Executive Officer, will be presenting at the 2024 Maxim Healthcare Virtual Summit. The summit is being held virtually on October 15 – 17, 2024. Event: Fireside Chat at 2024 Maxim Healthcare Virtual Summit Date: Thursday, October 17, 2024 Time: 3:00 PM ET Webcast: https://m-v.
Positive
Schwab Network
2 months ago
OSTX CEO: "We Have a Lot of Milestones Coming" in Tumor Research
Paul Romness, CEO of OS Therapies (OSTX), joins Nicole Petallides at the NYSE after the company recently completed a critical phase of its Osteosarcoma research. As OS Therapies readies to send its data to the FDA, Paul discusses the similarities of the disease between humans and dogs and looks ahead to researching other solid tumors.
Neutral
Business Wire
2 months ago
OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Completes Last Patient Visit
NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announces that the last patient (Patient #41) enrolled in the AOST-2121 clinical trial (NCT04974008) of OST-HER2 in recurred, resected Osteosarcoma (OS) has completed their final radiographical evaluation at 52 weeks and the treatment period for the clinical trial has now ended. The Company is preparing to re.
Neutral
Business Wire
2 months ago
OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates
NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced the development and in vitro concept data for two novel ADC therapeutic candidates leveraging the Company's proprietary SiLinker™ technology. The Company has completed target engagement tests for both therapeutic candidates and confirmed their therapeutic potential. These new constructs will t.
Positive
Proactive Investors
2 months ago
OS Therapies reports positive preclinical data for ovarian cancer treatment
OS Therapies Inc (NYSE-A:OSTX) announced encouraging preclinical results for its first therapeutic candidate targeting ovarian cancer. Preclinical data derived from tests conducted on KB and IGROV-1 mouse models of ovarian cancer demonstrated strong antitumor activity, the company said in a statement.
Charts implemented using Lightweight Charts™